HUE058852T2 - Lizinspecifikus demetiláz-1 inhibitorai - Google Patents

Lizinspecifikus demetiláz-1 inhibitorai

Info

Publication number
HUE058852T2
HUE058852T2 HUE15814038A HUE15814038A HUE058852T2 HU E058852 T2 HUE058852 T2 HU E058852T2 HU E15814038 A HUE15814038 A HU E15814038A HU E15814038 A HUE15814038 A HU E15814038A HU E058852 T2 HUE058852 T2 HU E058852T2
Authority
HU
Hungary
Prior art keywords
lysine
inhibitors
specific demethylase
demethylase
specific
Prior art date
Application number
HUE15814038A
Other languages
English (en)
Hungarian (hu)
Inventor
Young K Chen
Toufike Kanouni
Zhe Nie
Jeffrey Alan Stafford
James Marvin Veal
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of HUE058852T2 publication Critical patent/HUE058852T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HUE15814038A 2014-07-03 2015-06-29 Lizinspecifikus demetiláz-1 inhibitorai HUE058852T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462020886P 2014-07-03 2014-07-03

Publications (1)

Publication Number Publication Date
HUE058852T2 true HUE058852T2 (hu) 2022-09-28

Family

ID=55019883

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15814038A HUE058852T2 (hu) 2014-07-03 2015-06-29 Lizinspecifikus demetiláz-1 inhibitorai
HUE19156976A HUE062558T2 (hu) 2014-07-03 2015-06-29 Lizinspecifikus demetiláz-1 inhibitorok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE19156976A HUE062558T2 (hu) 2014-07-03 2015-06-29 Lizinspecifikus demetiláz-1 inhibitorok

Country Status (29)

Country Link
US (3) US9902719B2 (enExample)
EP (2) EP3164380B1 (enExample)
JP (2) JP6663866B2 (enExample)
KR (1) KR102475498B1 (enExample)
CN (2) CN108530424B (enExample)
AU (1) AU2015284383B2 (enExample)
BR (1) BR112017000043A2 (enExample)
CA (1) CA2954049A1 (enExample)
CL (1) CL2016003422A1 (enExample)
CO (1) CO2017000549A2 (enExample)
CY (1) CY1125127T1 (enExample)
DK (2) DK3164380T3 (enExample)
EA (2) EA201891526A3 (enExample)
EC (1) ECSP17006821A (enExample)
ES (2) ES2907676T3 (enExample)
FI (1) FI3511319T3 (enExample)
HR (2) HRP20230595T1 (enExample)
HU (2) HUE058852T2 (enExample)
IL (2) IL249881B (enExample)
LT (2) LT3164380T (enExample)
MX (2) MX376207B (enExample)
PL (2) PL3164380T3 (enExample)
PT (2) PT3164380T (enExample)
RS (2) RS63074B1 (enExample)
SA (1) SA517380651B1 (enExample)
SG (2) SG10201802501RA (enExample)
SI (2) SI3164380T1 (enExample)
SM (2) SMT202300205T1 (enExample)
WO (1) WO2016003917A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
CA3071804A1 (en) 2017-08-03 2019-02-07 Oryzon Genomics, S.A. Use of a kdm1a inhibitor in the treatment of behavior alterations
SG11202100199UA (en) * 2018-08-10 2021-02-25 Navire Pharma Inc 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
JP7532386B2 (ja) 2019-02-01 2024-08-13 ハンミ ファーマシューティカルズ カンパニー リミテッド イミダゾピリジン誘導体化合物及びその用途
CN113365996B (zh) * 2019-02-01 2024-09-03 韩美药品株式会社 咪唑吡啶衍生化合物以及药物组成物
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
HRP20260110T1 (hr) 2019-03-20 2026-03-13 Oryzon Genomics, S.A. Vafidemstat za liječenje neagresivnih simptoma graničnog poremećaja osobnosti
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Kdm1a阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
US11360505B2 (en) 2020-02-11 2022-06-14 Simmonds Precision Products, Inc. Distributed network time synchronization
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
CN117015540A (zh) * 2021-03-11 2023-11-07 南京明德新药研发有限公司 噻吩类化合物及其应用
CN117062813A (zh) * 2021-03-24 2023-11-14 四川汇宇制药股份有限公司 一种多环化合物及其应用
MX2023011779A (es) 2021-04-08 2023-11-22 Oryzon Genomics Sa Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides.
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
AU2002214546A1 (en) * 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
JP2005170792A (ja) * 2002-11-22 2005-06-30 Mitsubishi Pharma Corp L−プロリン誘導体およびその医薬としての用途。
US7504423B2 (en) 2003-12-11 2009-03-17 Mitsubishi Tanabe Pharma Corporation α-amino acid derivatives and use thereof as medicines
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
WO2006129181A2 (en) * 2005-06-03 2006-12-07 Orchid Research Laboratories Limited Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
BRPI0615048A2 (pt) * 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
JP2007197324A (ja) 2006-01-23 2007-08-09 Toray Ind Inc 2,4,5−置換−1,3−アゾール誘導体
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
PE20081803A1 (es) 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
WO2011130515A1 (en) * 2010-04-14 2011-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
IN2014MN01756A (enExample) * 2012-03-06 2015-07-03 Lupin Ltd
CA3161836A1 (en) * 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
RU2016136091A (ru) * 2014-02-14 2018-03-19 Дзе Юниверсити Оф Бритиш Коламбиа Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения
PE20161438A1 (es) * 2014-05-01 2017-01-18 Celgene Quanticel Res Inc Inhibidores de desmetilasa 1 especifica a lisina
FR3020945B1 (fr) 2014-05-16 2016-05-06 Oreal Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier
PL3160956T3 (pl) * 2014-06-27 2020-11-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy-1 specyficznej dla lizyny
CA2954060A1 (en) * 2014-07-03 2016-01-07 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1

Also Published As

Publication number Publication date
LT3164380T (lt) 2022-06-27
SI3164380T1 (sl) 2022-06-30
HRP20220414T1 (hr) 2022-05-27
CL2016003422A1 (es) 2017-11-10
KR20170018100A (ko) 2017-02-15
IL249881B (en) 2020-01-30
SI3511319T1 (sl) 2023-10-30
LT3511319T (lt) 2023-08-25
US20180127408A1 (en) 2018-05-10
ES2907676T3 (es) 2022-04-26
JP6663866B2 (ja) 2020-03-13
EP3164380A1 (en) 2017-05-10
BR112017000043A2 (pt) 2018-07-17
IL272130A (en) 2020-03-31
IL249881A0 (en) 2017-03-30
EP3511319A1 (en) 2019-07-17
US9902719B2 (en) 2018-02-27
MX2020010900A (es) 2022-09-13
SG11201610975RA (en) 2017-01-27
AU2015284383B2 (en) 2019-04-18
WO2016003917A1 (en) 2016-01-07
EA201790085A1 (ru) 2017-08-31
PT3164380T (pt) 2022-03-02
MX395534B (es) 2025-03-25
FI3511319T3 (fi) 2023-07-20
PL3511319T3 (pl) 2023-09-11
CN106795103B (zh) 2019-07-12
CA2954049A1 (en) 2016-01-07
JP2017525668A (ja) 2017-09-07
CO2017000549A2 (es) 2017-04-20
AU2015284383A1 (en) 2017-02-02
CN108530424A (zh) 2018-09-14
PT3511319T (pt) 2023-06-29
KR102475498B1 (ko) 2022-12-07
US20170129882A1 (en) 2017-05-11
JP2019108346A (ja) 2019-07-04
EP3511319B1 (en) 2023-05-03
JP6768857B2 (ja) 2020-10-14
EA033698B1 (ru) 2019-11-18
MX2017000168A (es) 2017-05-01
SMT202200136T1 (it) 2022-05-12
RS64423B1 (sr) 2023-09-29
DK3164380T3 (da) 2022-03-28
ECSP17006821A (es) 2017-03-31
EA201891526A3 (ru) 2019-05-31
US10100046B2 (en) 2018-10-16
MX376207B (es) 2025-03-07
CN108530424B (zh) 2021-10-01
DK3511319T3 (da) 2023-07-31
ES2948782T3 (es) 2023-09-19
IL272130B (en) 2021-03-25
US20190002456A1 (en) 2019-01-03
EP3164380A4 (en) 2018-07-18
EP3164380B1 (en) 2022-02-09
HUE062558T2 (hu) 2023-11-28
SG10201802501RA (en) 2018-05-30
SMT202300205T1 (it) 2023-09-06
CY1125127T1 (el) 2024-02-16
EA201891526A2 (ru) 2018-12-28
PL3164380T3 (pl) 2022-04-04
RS63074B1 (sr) 2022-04-29
SA517380651B1 (ar) 2020-09-30
CN106795103A (zh) 2017-05-31
HRP20230595T1 (hr) 2023-09-15

Similar Documents

Publication Publication Date Title
FIC20240044I1 (fi) Odronekstamabi
NO2023039I1 (no) Glofitamab
FIC20240035I1 (fi) Toferseeni
FIC20240015I1 (fi) Zilbrysq - tsilukoplaani
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HUE050564T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
LT3164380T (lt) Lizinui specifiniai demetilazės-1 inhibitoriai
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3442972T3 (da) Bromdomænehæmmere
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3171891T3 (da) Fremgangsmåde
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
LT3160952T (lt) Histono demetilazės inhibitoriai
DK3341379T3 (da) EZH2-hæmmere
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
FIC20240047I1 (fi) Frukintinibi
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DE112015001664A5 (de) Betätigungsaktuator
DE112015005041A5 (de) Gargerätevorrichtung
DE102014000623A8 (de) Halbhohlnietelement
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DE202014005655U8 (de) llluminationsvorrichtung
DE112015001633A5 (de) Betätigungsaktuator